Catalyst Pharmaceuticals (CPRX) Receives Media Impact Score of 0.21

Press coverage about Catalyst Pharmaceuticals (NASDAQ:CPRX) has been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Catalyst Pharmaceuticals earned a daily sentiment score of 0.21 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.2659725293158 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Shares of Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $3.93 on Friday. The stock has a market cap of $338.16, a PE ratio of -18.71 and a beta of 1.68. Catalyst Pharmaceuticals has a 12 month low of $1.03 and a 12 month high of $4.51.

A number of equities analysts have commented on CPRX shares. Zacks Investment Research lowered shares of Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday, November 10th. Roth Capital set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 1st. Piper Jaffray Companies set a $8.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, SunTrust Banks set a $5.00 price objective on shares of Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $6.25.

COPYRIGHT VIOLATION NOTICE: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark & copyright legislation. The correct version of this news story can be accessed at https://sportsperspectives.com/2018/01/13/catalyst-pharmaceuticals-cprx-receives-media-impact-score-of-0-21.html.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Insider Buying and Selling by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply